213 related articles for article (PubMed ID: 20129393)
1. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center).
Heigl F; Hettich R; Lotz N; Reeg H; Eder B; Steckholzer-Kroth K; Browatzki M; Harre K; Arendt R
Atheroscler Suppl; 2009 Dec; 10(5):137-41. PubMed ID: 20129393
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
Heigl F; Pflederer T; Klingel R; Hettich R; Lotz N; Reeg H; Schettler VJJ; Roeseler E; Grützmacher P; Hohenstein B; Julius U
Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
[TBL] [Abstract][Full Text] [Related]
3. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
[TBL] [Abstract][Full Text] [Related]
4. Rheopheresis for sudden sensorineural hearing loss.
Klingel R; Heibges A; Uygun-Kiehne S; Fassbender C; Mösges R
Atheroscler Suppl; 2009 Dec; 10(5):102-6. PubMed ID: 20129385
[TBL] [Abstract][Full Text] [Related]
5. Apheresis in treatment of acute inflammatory demyelinating disorders.
Mühlhausen J; Kitze B; Huppke P; Müller GA; Koziolek MJ
Atheroscler Suppl; 2015 May; 18():251-6. PubMed ID: 25936333
[TBL] [Abstract][Full Text] [Related]
6. Lipid apheresis and rheopheresis for treatment of peripheral arterial disease.
Weiss N
Atheroscler Suppl; 2009 Dec; 10(5):62-9. PubMed ID: 20129378
[TBL] [Abstract][Full Text] [Related]
7. The German Lipid Apheresis Registry - remaining to be established.
Schettler V; Jaeger BR; Klingel R;
Atheroscler Suppl; 2009 Dec; 10(5):59-61. PubMed ID: 20129377
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in therapeutic apheresis.
Bosch T
J Artif Organs; 2003; 6(1):1-8. PubMed ID: 14598117
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of long-term lipid apheresis at a single center.
Koziolek MJ; Hennig U; Zapf A; Bramlage C; Grupp C; Armstrong VW; Strutz F; Müller GA
Ther Apher Dial; 2010 Apr; 14(2):143-52. PubMed ID: 20438535
[TBL] [Abstract][Full Text] [Related]
10. Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias.
Grützmacher P; Kleinert C; Dorbath C; Öhm B
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):2-7. PubMed ID: 25686595
[TBL] [Abstract][Full Text] [Related]
11. Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2009 Dec; 10(5):129-32. PubMed ID: 20129391
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein apheresis standard for apheresis competence centers--an updated synthesis and amendment to pre-existing standards.
Heigl F; Hettich R; Eder B; Arendt R
Atheroscler Suppl; 2013 Jan; 14(1):57-65. PubMed ID: 23357142
[TBL] [Abstract][Full Text] [Related]
13. Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
Heigl F; Hettich R; Arendt R; Durner J; Koehler J; Mauch E
Atheroscler Suppl; 2013 Jan; 14(1):167-73. PubMed ID: 23357160
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein apheresis: principles and indications.
Winters JL
Semin Dial; 2012; 25(2):145-51. PubMed ID: 22277063
[TBL] [Abstract][Full Text] [Related]
15. Lipidfiltration--safe and effective methodology to perform lipid-apheresis.
Klingel R; Mausfeld P; Fassbender C; Goehlen B
Transfus Apher Sci; 2004 Jun; 30(3):245-54. PubMed ID: 15172630
[TBL] [Abstract][Full Text] [Related]
16. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques.
Kopprasch S; Graessler J; Bornstein SR; Schwarz PE; Tselmin S; Frind A; Poberschin I; Julius U
Atheroscler Suppl; 2009 Dec; 10(5):34-8. PubMed ID: 20129371
[TBL] [Abstract][Full Text] [Related]
17. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159
[TBL] [Abstract][Full Text] [Related]
18. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
[TBL] [Abstract][Full Text] [Related]
19. How will new medications affect the lipoprotein apheresis situation in Germany?
Parhofer KG
Atheroscler Suppl; 2013 Jan; 14(1):71-2. PubMed ID: 23357144
[TBL] [Abstract][Full Text] [Related]
20. Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
Kozik-Jaromin J; Röseler E; Heigl F; Spitthöver R; Ringel J; Schmitz G; Heinzler R; Abdul-Rahman N; Leistikow F; Himmelsbach F; Schettler V; Uhlenbusch-Körwer I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():225-231. PubMed ID: 29096842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
